Definitive Contract HHSN261201200088C

<p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute, a civilian agency, to Zymera Inc., a small disadvantaged business. The contract has a ceiling value of $199,948.00 and is for the development of homogeneous nanoparticle-based systems for protease detection. The contract was awarded on September 30, 2009 with a completion date of June 29, 2010. As this is an SBIR Phase I contract, it is a small business set-aside.</p>

This is a $299,998.00 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) program. The contract is for Phase I research and development related to &quot;Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics&quot;, as part of SBIR Topic...

This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Zymeron Corporation, a Minority Owned Small Business. The $349,790 Firm Fixed Price contract supports research and development of &quot;Targeted and Sustained Release Microparticles for Colon Cancer Chemoprevention.&quot; This work is part of the NIH/CDC SBIR Program, which aims to stimulate technological...

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This definitive contract award of $13,720 by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Zymeron Corporation is for the research and development of a rapid point-of-care test to screen for human papillomavirus in low-resource settings. The contract is associated with Solicitation PHS-2023-1 of the NIH and Centers for Disease Control and Prevention Small Business Innovation Research Program Phase I, which sought proposals to address...

Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Intezyne Technologies, Inc. for $187,222 to perform basic research and development work classified as &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL&quot;. The contract was awarded on September 20, 2012 and has a completion date of June 19, 2013. Intezyne Technologies is a for-profit organization, and this award was made under a total small business set-aside.

This is a federal contract award from the National Cancer Institute, a civilian agency, to Zoneone Pharma Inc., a small business contractor. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; with a ceiling value of $215,999.00. It is a definitive, firm fixed-price contract with a completion date of July 10, 2013. The place of performance is San Francisco, CA. As a small business set-aside award, this contract supports the National Cancer Institute's research...

<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>